PUBLICATIONS, NEWS & EVENTS
Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator
Support for clinical development up to end of Phase 2 for…
October 15, 2019/by adminECFS Clinical Meeting Liverpool TMEM16A potentiator
ECFS Clinical Meeting Liverpool TMEM16A potentiator
Objectives:…
October 9, 2019/by adminObjectives:…
A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies?
A systematic comparison of the profiles of inhaled ENaC blocker…
October 9, 2019/by adminSomething old and something new: ENaC & TMEM16A as targets to hydrate mucus in the CF airway
Something old and something new: ENaC & TMEM16A as targets…
October 9, 2019/by adminThe pharmacology of novel TMEM16A potentiator compounds
The pharmacology of novel TMEM16A potentiator compounds
Henry…
April 2, 2019/by adminHenry…
EACT increases intracellular calcium levels by a TMEM16A-independent mechanism
EACT increases intracellular calcium levels by a TMEM16A-independent…
April 2, 2019/by adminEnterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman
Appointment brings significant commercial pharma experience as…
March 25, 2019/by adminGordon Research Conference ‘Modeling and Targeting Mucociliary Function in Health and Disease: Genes to Cells to Interaction Networks and Tissues’ February 2019
Identifying pathways & compounds regulating goblet cell metaplasia…
February 20, 2019/by adminEnterprise Therapeutics selected as a finalist for Scrip Awards and Lifestars Awards
Scrip Awards 2018 “Financing Deal of the Year- Private”…
October 4, 2018/by admin32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 210
Submission: 210 - PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE…
September 28, 2018/by admin32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 89
Submission: 89 - IDENTIFYING PATHWAYS REGULATING GOBLET CELL…
September 28, 2018/by adminEnterprise Therapeutics raises £29 million ($41 million USD) funding
Brighton, UK – 12 April 2018: Enterprise Therapeutics Ltd (Enterprise),…
April 12, 2018/by admin
